Drug Utilization Review Board
Minutes Draft

Name of Meeting: Drug Utilization Review Board
Date of Meeting: May 12, 2016
Length of Meeting: 2 hour and 15 minutes
Location of Meeting: DMAS Board Room 13th Floor

Members Present:
Randy Ferrance, MD, Chair
Bill Rock, PharmD, Vice Chair
Avtar Dhillon, MD
Kathryn Reid, PhD
Seth Brant, MD
Sandra Dawson, RPh
Jonathan Evans, MD

Members Not Present:
Denese Gomes, NP
Michele Thomas, PharmD
Wendy Nash, PharmD

DMAS Attendees:
Donna Proffitt, RPh, Pharmacy Program Manager
Rachel Cain, PharmD
Danielle Adeeb, CPhT
Dacia Henry, Program Integrity
Tyrone Wall

Contractors:
MaryAnn McNeil, RPh, Clinical Pharmacy Manager, Xerox
Glendora Richardson, Xerox

Vendors:
Debbie Moody, RPh, Magellan Health Services
Nancy Eldin, PharmD, Magellan Health Services

Visitors:
Tracey Pulliam, Purdue
James Moore,Taiho
Steve Zegarski, Purdue
Paula Pitman-Kupresak, AbbVie
Olivier Peram, Taiho
David Sherron, UCB
Donald Medlin, UCB
Scott Friedly, Takeda
Ken Jennings, BMS

Call to Order and Introductions

Dr. Ferrence called the meeting to order at 2:15pm.

Minutes – November 12, 2015

Meeting minutes were reviewed and approved.

NEW Drugs

Alecensa® (Alectinib HCL) - M. McNeil presented the drug information and service authorization criteria recommendations. The motion was made to accept the criteria as written for Alecensa®. The Board seconded and approved the criteria.

Cotellic™ (Cobimetnib) - M. McNeil presented the drug information and service authorization criteria recommendations. The motion was made to accept the criteria as written for Cotellic™. The Board seconded and approved the criteria.

Lonsurf® (Trifluridine/Tipircil Hcl) - M. McNeil presented the drug information and service authorization criteria recommendations. The motion was made to accept the criteria as written for Lonsurf®. The Board seconded and approved the criteria.

Ninlaro® (Ixazomib Citrate) - M. McNeil presented the drug information and service authorization criteria recommendations. The motion was made to accept the criteria as written for Ninlaro®. The Board seconded and approved the criteria.

Tagrisso™ (Osimertinib Mesylate) - M. McNeil presented the drug information and service authorization criteria recommendations. The motion was made to accept the criteria as written for Tagrisso™. The Board seconded and approved the criteria.

Genvoya® (Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate) - M. McNeil presented the drug information and service authorization criteria recommendations. The motion was made to accept the criteria as written for Genvoya®. The Board seconded and approved the criteria.

Evzio® Naloxone HCL - M. McNeil presented the drug information and service authorization criteria recommendations. The motion was made to accept the criteria as written for Evzio®. The Board seconded and approved the criteria.

Narcan® Nasal Spray (Naloxone HCL) - M. McNeil presented the drug information and service authorization criteria recommendations. The motion was made to accept the criteria as written for Narcan®. The Board seconded and approved the criteria.

Veltassa™ (Patiromer Calcium Sorbitex) – M. McNeil presented the drug information and service authorization criteria recommendations for Veltassa™. The motion was made to accept the criteria as written. The Board seconded and approved the criteria.

Odefsey® (Emtricitabine, Rilpivirine, and Tenofovir Alafenamide) - M. McNeil presented the drug information and service authorization criteria recommendations for Odefsey. The motion was made to accept the criteria as written. The Board seconded and approved the criteria.

New Drugs: Physicians-administered - M. McNeil presented the drug information for New Physician-administered Drugs. The motion was made to accept the criteria as written. The Board seconded and approved the criteria.

PDL Eligible Drugs reviewed - M. McNeil presented the drug information for PDL Eligible Drugs. The motion was made to accept the criteria as written. The Board seconded and approved the criteria.

Service Authorizations

Revlimid® - One prior therapy treatment indication is no longer required for authorization. The motion was made to accept the changes as written. The Board seconded and approved the changes.

Iclusig® - Based on new indications, previous therapy requirements on the service authorization form were removed. The motion was made to accept the changes as written. The Board seconded and approved the changes.

Ibrance® - New indication states this drug can be used for either pre or post-menopausal patients. The motion was made to accept the changes as written. The Board seconded and approved the changes.

Topics for Discussion

Hydrocodone Utilization - Xerox presented information from The Journal of the American Medical Association (JAMA) *Internal Medicine* which noted that hydrocodone combination prescriptions have dropped 22% since the rescheduling of hydrocodone substances from schedule III to schedule II controlled substance by the U.S. Drug Enforcement Agency (DEA). DMAS also reported a 22% decrease in the number of Hydrocodone claims from 2014 – 2015.

Buprenorphine – Xerox shared claim specific information on patients who were receiving Buprenorphine and a narcotic or benzodiazepine. The results of the analysis revealed that there were 7 patients that went to 29 different prescribers and did not follow the treatment plans; Xerox recommends letters be sent to pharmacies and prescribers to communicate with the providers regarding non-compliant patients. Xerox will draft a letter for approval by DMAS. The Board requests Xerox continue this report going forward.

Morphine Equivalent Dosing and Narcotic Quantity Limits: It has been determined that the Virginia Medicaid Pharmacy and Therapeutics (P&T) Committee will make all the determinations for narcotic limits for those recipients 18 years and older. New quantity and dosage limits will start July 1st in the Point Of Sale (POS) system. DMAS requested the DUR Board make dosage recommendations for pediatric narcotics limits. The Board has requested Xerox collect utilization data based on age, prescription day's supply (less than 14 days and greater than 14 days) and diagnosis over 6 month period. A subcommittee will review this data and present the finding at the August DUR meeting.

Compounded Prescriptions – Due to concern of topical compounded products, the Board recommended letters be sent to prescribers for all compounded prescriptions dispensed in the last six months. The letters will include a request of prescribing information for FDA indications and evidence-based safety and efficacy for patient use. Xerox to present data at August meeting.

Dose Optimization – DMAS requested to focus on updating the Point-of-sale system with clinically appropriate edits in terms of dose optimization and maximum quantities dispensed beyond the 34 days logic. The Quantity limit edits will be staggered in the POS system. In addition, a request was made that Xerox provide utilization reports above recommended limits to the board at the August meeting.

Synagis- Xerox presented Synagis claims data for Respiratory Syncytial Virus (RSV) seasons 10/1/10 to 3/31/11, 10/1/14 to 3/31/15 and current season 10/1/15 to 3/31/16. Results show continued decrease in claims volume and utilizing members. The majority of patients continue to be less than 2 years of age as FDA indicated.

Reports

ProDUR and RetroDUR- M. McNeil reviewed reports provided in the DUR Board binder.

Utilization Analysis Reports- M. McNeil reviewed the Top 25 Drugs Ranked by Claim Count, by Payment Amount and the Cost Utilization Analysis by Drug Type provided in the DUR Board binder.

Top Diagnoses by Age- M. McNeil reviewed the Top Diagnoses by Age for all ages provided in the DUR Board Binder.

AAP Report- M. McNeil reviewed the report provided in the DUR Board binder.

By-Laws - Tabled until August meeting.

Meeting was adjourned at 4:30 pm.

Upcoming DUR Board meetings are scheduled for August 11 and November 10th 2016.